Holen Sie sich die Stockscreener-App
11.59
0.09%
0.010
Handel nachbörslich:
11.73
0.14
+1.21%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$11.58
Offen:
$11.5
24-Stunden-Volumen:
2.71M
Relative Volume:
0.48
Marktkapitalisierung:
$2.31B
Einnahmen:
$3.68B
Nettoeinkommen (Verlust:
$-627.00M
KGV:
-3.6821
EPS:
-3.1477
Netto-Cashflow:
$104.00M
1W Leistung:
-4.37%
1M Leistung:
-8.74%
6M Leistung:
-10.50%
1J Leistung:
-16.44%
1-Tages-Spanne:
$11.46
$11.88
1-Wochen-Bereich:
$11.21
$12.12
52-Wochen-Spanne:
$9.405
$14.86
Dentsply Sirona Inc Stock (XRAY) Company Profile
Firmenname
Dentsply Sirona Inc
Sektor
Telefon
844-546-3722
Adresse
13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE, NC
Compare XRAY vs ISRG, BDX, ALC, RMD, MDLN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XRAY
Dentsply Sirona Inc
|
11.59 | 2.27B | 3.68B | -627.00M | 104.00M | -3.1477 |
ISRG
Intuitive Surgical Inc
|
394.51 | 141.76B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
183.40 | 50.00B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
74.25 | 35.57B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
224.46 | 32.78B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
35.74 | 31.15B | 29.14B | 1.07B | 1.05B | 1.1956 |
Dentsply Sirona Inc Stock (XRAY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | Citigroup | Sell |
| 2026-02-19 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-12-09 | Eingeleitet | Barclays | Underweight |
| 2025-11-07 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-04-15 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-13 | Herabstufung | Needham | Buy → Hold |
| 2025-02-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2025-01-23 | Herabstufung | Jefferies | Buy → Hold |
| 2025-01-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-12-04 | Eingeleitet | Mizuho | Neutral |
| 2024-11-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-10-25 | Bestätigt | Needham | Buy |
| 2024-08-20 | Bestätigt | Needham | Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-16 | Eingeleitet | Needham | Buy |
| 2023-11-10 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-01-12 | Hochstufung | William Blair | Underperform → Mkt Perform |
| 2022-08-05 | Herabstufung | William Blair | Mkt Perform → Underperform |
| 2022-06-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-04-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-04-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2022-04-19 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-04-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-01-31 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-10-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-08-09 | Bestätigt | H.C. Wainwright | Neutral |
| 2021-08-06 | Bestätigt | Barrington Research | Outperform |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-02 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2021-03-02 | Bestätigt | H.C. Wainwright | Neutral |
| 2021-01-05 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-12-18 | Herabstufung | Stifel | Buy → Hold |
| 2020-11-17 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-10-22 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-08-10 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-06-16 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-15 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-05-27 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-05-11 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-04-24 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-04-08 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2020-04-07 | Herabstufung | Goldman | Buy → Neutral |
| 2020-04-02 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-03-03 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-02-19 | Bestätigt | Stifel | Buy |
| 2019-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-08-02 | Hochstufung | Wellington Shields | Hold → Gradually Accumulate |
| 2019-07-26 | Eingeleitet | Evercore ISI | In-line |
| 2019-07-09 | Bestätigt | H.C. Wainwright | Neutral |
| 2019-05-30 | Eingeleitet | Wolfe Research | Peer Perform |
Alle ansehen
Dentsply Sirona Inc Aktie (XRAY) Neueste Nachrichten
Royal Bank of Canada Raises Holdings in DENTSPLY SIRONA Inc. $XRAY - marketbeat.com
The 5 Most Interesting Analyst Questions From Dentsply Sirona’s Q2 Earnings Call - Yahoo Finance
DENTSPLY Sirona Inc (XRAY) News, Articles, Events & Latest Updates - Stocktwits
Dentsply Sirona (XRAY): Southpoint reports 7M-share, 3.5% ownership in 13G/A - Stock Titan
Dentsply Sirona (XRAY) Q2 2026 Earnings Call Transcript - The Globe and Mail
Is DENTSPLY SIRONA’s (XRAY) Steady Buyback and Reaffirmed Outlook Reframing Its Risk‑Reward Profile? - simplywall.st
DENTSPLY SIRONA (XRAY) gains AQR Capital as 5.22% beneficial owner - Stock Titan
DS World Las Vegas 2026 connects clinical and laboratory education - Dental Tribune US
DENTSPLY SIRONA (XRAY) CFO awarded 104,200 stock options and 24,014 RSUs - Stock Titan
Pacer Advisors Inc. Has $266,000 Stake in DENTSPLY SIRONA Inc. $XRAY - marketbeat.com
DENTSPLY SIRONA (XRAY) SVP Frohning reports 802 tax-withheld shares - Stock Titan
XRAY Q2 Deep Dive: Turnaround Progress Slowed by Market and Segment Headwinds - Yahoo Finance
DENTSPLY SIRONA (XRAY): Navigating Challenges With A 17.66% Potential Upside - DirectorsTalk Interviews
Why Dentsply Sirona (XRAY) Stock Is Trading Lower Today - Yahoo Finance
Dentsply Sirona Earnings: Weak Recovery Momentum Unchanged as Soft Volume Weighs on Results - Morningstar
Empowered Funds LLC Grows Stake in DENTSPLY SIRONA Inc. $XRAY - marketbeat.com
Dentsply Sirona (XRAY) Stock Drops As Revenue Weakens Despite Profit Rebound - Sahm
DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Receives Average Recommendation of "Hold" from Analysts - marketbeat.com
Form 8K Dentsply Sirona Inc For: 7 August By Investing.com - Investing.com Nigeria
DENTSPLY SIRONA Q2 Earnings Call Highlights - marketbeat.com
1% Undervalued? DENTSPLY SIRONA (XRAY) As Earnings Test Its Recovery Story - Yahoo Finance
Dentsply Sirona Reports $898 Million in Net Sales for Second Quarter 2026 - Orthodontic Products
Dentsply's Full Recovery Timeline Looks Uncertain as Tough Market and Competition Put Pressure - Morningstar
XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales - Yahoo Finance
DENTSPLY SIRONA (NASDAQ:XRAY) Trading Down 8.4%Here's What Happened - MarketBeat
A Quick Look at Today's Ratings for Dentsply Sirona(XRAY.US), With a Forecast Between $9 to $15 - Moomoo
DENTSPLY SIRONA Inc. Q2 2026 Earnings Call Summary - finance.yahoo.com
DENTSPLY SIRONA Inc. Stock 12‑Month Price Target Raised to $13.7, Implies 4% Upside - TradingView
DENTSPLY SIRONA Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:XRAY) 2026-08-06 - Seeking Alpha
Earnings call transcript: DENTSPLY Sirona posts slight q2 2026 revenue beat, shares fall - Investing.com
DENTSPLY SIRONA (NASDAQ:XRAY) Issues Earnings Results - MarketBeat
DENTSPLY SIRONA (NASDAQ:XRAY) Releases FY 2026 Earnings Guidance - marketbeat.com
Dentsply International (XRAY) Beats Q2 Earnings and Revenue Estimates - finance.yahoo.com
Transcript : DENTSPLY SIRONA Inc., Q2 2026 Earnings Call, Aug 06, 2026 - marketscreener.com
DENTSPLY SIRONA Inc. 2026: Revenue $898M, EPS $0.18— 10-Q Summary - TradingView
DENTSPLY SIRONA Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
[10-Q] DENTSPLY SIRONA Inc. Quarterly Earnings Report - Stock Titan
Tranche Update on DENTSPLY SIRONA Inc.'s Equity Buyback Plan announced on March 16, 2005. - marketscreener.com
DENTSPLY SIRONA ($XRAY) Releases Q2 2026 Earnings, Stock Rises - Quiver Quantitative
Dentsply Sirona (NASDAQ:XRAY) Beats Q2 CY2026 Sales Expectations - Yahoo Finance
Earnings Flash (XRAY) DENTSPLY SIRONA Inc. Reports Q2 Revenue $898.0M, vs. FactSet Est of $889.9M - marketscreener.com
DENTSPLY SIRONA (XRAY): First Eagle discloses 851,347-share position in 13G/A - Stock Titan
Earnings Flash (XRAY) DENTSPLY SIRONA Inc. Posts Q2 Adjusted EPS $0.52 per Share - marketscreener.com
Dentsply Sirona Reports Second Quarter 2026 Results - marketscreener.com
BRIEF-Dentsply Sirona Q2 Revenue USD 898 Million Vs. IBES Estimate USD 889.8 Million - TradingView
DENTSPLY SIRONA Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Dentsply Sirona investors brace for earnings amid Medline threat By Investing.com - Investing.com Nigeria
Expanded Medline Sinclair Tech Distribution in Canada Could Be A Game Changer For DENTSPLY SIRONA (XRAY) - simplywall.st
Arkadios Wealth Advisors Purchases New Stake in DENTSPLY SIRONA Inc. $XRAY - MarketBeat
Dental products manufacturer keeps 2026 sales outlook at $3.5B-$3.6B - Stock Titan
Earnings To Watch: Dentsply Sirona (XRAY) Reports Q2 Results Tomorrow - The Globe and Mail
Finanzdaten der Dentsply Sirona Inc-Aktie (XRAY)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.90%
1.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):